Safety and Efficacy of Triple Combination Therapy in Patients with Glaucoma or Ocular Hypertensio
Phase 3
- Registration Number
- CTRI/2010/091/002922
- Lead Sponsor
- Allergan India Private Limited, Level 2, Prestige Obelisk, No. 3 Kasturba Road, Bangalore, Karnataka, IndiaAllergan, Inc., Irvine, California, USA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 120
Inclusion Criteria
Glaucoma and/or ocular hypertension in both eyes
-Requires IOP-lowering treatment in both eyes
Exclusion Criteria
-Other active ocular disease other than glaucoma or ocular hypertension (eg, uveitis, ocular infections or severe dry eye)
-Required chronic use of ocular medications other than study medications, except for intermittent use of artificial tears
-Use of oral, injectable or topical corticosteroids within 21 days
-Any eye laser surgery within 3 months
-Any intraocular surgery (eg, cataract surgery) within 6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method